RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D.
Emde-Rajaratnam M, et al. Among authors: beck s.
Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023.
Front Immunol. 2023.
PMID: 38035078
Free PMC article.